Details of the Drug

General Information of Drug (ID: DMTK234)

Drug Name

Piroxicam

Synonyms

Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1], [2]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

331.3

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is well absorbed after oral administration [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
Elimination: 5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 30 - 86 hours [6]
Metabolism: The drug is metabolized via renal [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.51 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 0.14 L/kg [8]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0073 mg/mL [4]

Chemical Identifiers

Formula: C15H13N3O4S
IUPAC Name: 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
Canonical SMILES: CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
InChI: InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
InChIKey: QYSPLQLAKJAUJT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 54676228
ChEBI ID: CHEBI:8249
CAS Number: 36322-90-4
DrugBank ID: DB00554
TTD ID: D00IBN
VARIDT ID: DR00481
INTEDE ID: DR1300
ACDINA ID: D00537

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Modulator	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Pain

ICD Disease Classification

MG30-MG3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 1 (COX-1)	DTT	PTGS1	3.97E-03	0.16	0.43
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Piroxicam

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Aspirin.	Pain [MG30-MG3Z]	[37]
-----------

Coadministration of a Drug Treating the Disease Different from Piroxicam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[38]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Repaglinide.	Acute diabete complication [5A2Y]	[39]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Glibenclamide.	Acute diabete complication [5A2Y]	[39]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Tolazamide.	Acute diabete complication [5A2Y]	[39]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Nateglinide.	Acute diabete complication [5A2Y]	[39]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Glipizide.	Acute diabete complication [5A2Y]	[39]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Piroxicam caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[40]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[41]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Piroxicam and Cilostazol.	Arterial occlusive disease [BD40]	[42]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Piroxicam caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[38]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Budesonide.	Asthma [CA23]	[43]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Kanamycin.	Bacterial infection [1A00-1C4Z]	[45]
Trovafloxacin	DM6AN32	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Streptomycin.	Bacterial infection [1A00-1C4Z]	[45]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Piroxicam and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[44]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Piroxicam and ABT-492.	Bacterial infection [1A00-1C4Z]	[44]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Gentamicin.	Bacterial infection [1A00-1C4Z]	[45]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Netilmicin.	Bacterial infection [1A00-1C4Z]	[45]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Tobramycin.	Bacterial infection [1A00-1C4Z]	[45]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Etidronic acid.	Bone paget disease [FB85]	[46]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Risedronate.	Bone paget disease [FB85]	[46]
Alendronate	DMY2KX9	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Alendronate.	Bone paget disease [FB85]	[46]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Piroxicam and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[47]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Piroxicam caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[48]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Piroxicam and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[42]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Iodipamide.	Cholelithiasis [DC11]	[49]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Piroxicam and Regorafenib.	Colorectal cancer [2B91]	[40]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Piroxicam and Drospirenone.	Contraceptive management [QA21]	[50]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Methoxyflurane.	Corneal disease [9A76-9A78]	[40]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Piroxicam and Ardeparin.	Coronary thrombosis [BA43]	[51]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Piroxicam caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[52]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Piroxicam caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[53]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Piroxicam caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[54]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Piroxicam and Danaparoid.	Deep vein thrombosis [BD71]	[51]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Piroxicam and Rivaroxaban.	Deep vein thrombosis [BD71]	[55]
Aprepitant	DM053KT	Moderate	Increased metabolism of Piroxicam caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[56]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Piroxicam and Sertraline.	Depression [6A70-6A7Z]	[57]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Piroxicam and Vilazodone.	Depression [6A70-6A7Z]	[57]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Piroxicam and Paroxetine.	Depression [6A70-6A7Z]	[57]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Piroxicam and Vortioxetine.	Depression [6A70-6A7Z]	[57]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Piroxicam and Milnacipran.	Depression [6A70-6A7Z]	[57]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Piroxicam and Escitalopram.	Depression [6A70-6A7Z]	[57]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Piroxicam and Desvenlafaxine.	Depression [6A70-6A7Z]	[57]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Piroxicam and Clomipramine.	Depression [6A70-6A7Z]	[57]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Piroxicam and PMID28870136-Compound-49.	Discovery agent [N.A.]	[58]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Piroxicam and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[57]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Cannabidiol.	Epileptic encephalopathy [8A62]	[40]
Benzthiazide	DMQWZ0H	Moderate	Antagonize the effect of Piroxicam when combined with Benzthiazide.	Essential hypertension [BA00]	[59]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Piroxicam and Tazemetostat.	Follicular lymphoma [2A80]	[42]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Piroxicam and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[40]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Piroxicam and Sulfinpyrazone.	Gout [FA25]	[42]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Piroxicam and Eplerenone.	Heart failure [BD10-BD1Z]	[60]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Piroxicam when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[59]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Piroxicam when combined with Furosemide.	Heart failure [BD10-BD1Z]	[59]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Piroxicam when combined with Amiloride.	Heart failure [BD10-BD1Z]	[59]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Piroxicam when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[59]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Piroxicam when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[59]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Piroxicam caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[61]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[62]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Piroxicam caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Piroxicam caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[38]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Piroxicam and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[65]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Piroxicam and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[66]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Piroxicam and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[67]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Piroxicam when combined with Indapamide.	Hypertension [BA00-BA04]	[59]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Piroxicam when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[59]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Piroxicam when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[68]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Piroxicam and Dipyridamole.	Hypertension [BA00-BA04]	[42]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Piroxicam and Potassium chloride.	Hypo-kalaemia [5C77]	[69]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[43]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Balsalazide.	Indeterminate colitis [DD72]	[70]
Methotrexate	DM2TEOL	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Methotrexate.	Leukaemia [2A60-2B33]	[71]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Piroxicam and Porfimer Sodium.	Lung cancer [2C25]	[72]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Piroxicam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[38]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Piroxicam and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[73]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Idelalisib.	Mature B-cell leukaemia [2A82]	[74]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Piroxicam and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[75]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Clofarabine.	Mature B-cell lymphoma [2A85]	[40]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Piroxicam and Ibrutinib.	Mature B-cell lymphoma [2A85]	[76]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Piroxicam and Ponatinib.	Mature B-cell lymphoma [2A85]	[77]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Piroxicam caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[40]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Exjade.	Mineral absorption/transport disorder [5C64]	[78]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Piroxicam and Panobinostat.	Multiple myeloma [2A83]	[38]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Piroxicam and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[42]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Piroxicam and Dasatinib.	Myeloproliferative neoplasm [2A20]	[79]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Piroxicam and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[80]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Piroxicam and Prasugrel.	Myocardial infarction [BA41-BA43]	[40]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Piroxicam and Vorapaxar.	Myocardial infarction [BA41-BA43]	[81]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Piroxicam and Tirofiban.	Myocardial infarction [BA41-BA43]	[82]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Piroxicam and Sibutramine.	Obesity [5B80-5B81]	[57]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Piroxicam and Dexfenfluramine.	Obesity [5B80-5B81]	[57]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Piroxicam when combined with Polythiazide.	Oedema [MG29]	[59]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Diclofenac.	Osteoarthritis [FA00-FA05]	[83]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Piroxicam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[84]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Piroxicam and MK-4827.	Ovarian cancer [2C73]	[40]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Prednisone.	Postoperative inflammation [1A00-CA43]	[43]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[43]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Piroxicam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[85]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Piroxicam caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[86]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Piroxicam and Epoprostenol.	Pulmonary hypertension [BB01]	[87]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Piroxicam and Iloprost.	Pulmonary hypertension [BB01]	[87]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Temsirolimus.	Renal cell carcinoma [2C90]	[88]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[44]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Sulfasalazine.	Rheumatoid arthritis [FA20]	[70]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Piroxicam and Leflunomide.	Rheumatoid arthritis [FA20]	[66]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[40]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[43]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Pitolisant.	Somnolence [MG42]	[40]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Piroxicam and Naltrexone.	Substance abuse [6C40]	[89]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Piroxicam and Caplacizumab.	Thrombocytopenia [3B64]	[42]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Piroxicam and Apixaban.	Thrombosis [DB61-GB90]	[40]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Piroxicam and Cangrelor.	Thrombosis [DB61-GB90]	[42]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Piroxicam and Brilinta.	Thrombosis [DB61-GB90]	[40]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Piroxicam and Cabozantinib.	Thyroid cancer [2D10]	[90]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Sirolimus.	Transplant rejection [NE84]	[88]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Piroxicam and Tacrolimus.	Transplant rejection [NE84]	[88]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[39]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Piroxicam and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[39]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Olsalazine.	Ulcerative colitis [DD71]	[70]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Cinoxacin.	Urinary tract infection [GC08]	[44]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Piroxicam and Plazomicin.	Urinary tract infection [GC08]	[45]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS stimulant effects by the combination of Piroxicam and Nalidixic acid.	Urinary tract infection [GC08]	[44]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Piroxicam and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[43]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Piroxicam and Betrixaban.	Venous thromboembolism [BD72]	[91]
-----------


⏷ Show the Full List of 129 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Ethylene glycol ethyl ether	E00164	8076	Solubilizing agent; Solvent
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Piroxicam 10 mg capsule	10 mg	Oral Capsule	Oral
Piroxicam 20 mg capsule	20 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7273).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073535.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10	Functional characterization of human CYP2C9 allelic variants in COS-7 cells. Front Pharmacol. 2016 Apr 25;7:98.
11	Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9 J Pain Res. 2017 Jul 6;10:1581-1589.
12	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
13	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
14	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
15	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
16	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
17	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
18	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
19	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
20	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
21	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
22	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
23	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
24	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
25	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
26	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
27	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
28	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
29	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
30	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
31	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
32	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
33	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
34	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
35	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
36	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
37	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
38	Cerner Multum, Inc. "Australian Product Information.".
39	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
40	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
43	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
44	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
45	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
46	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
47	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
48	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
50	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
51	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
52	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
53	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
54	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
55	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
56	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
57	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
58	Canadian Pharmacists Association.
59	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
60	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
61	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
62	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
63	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
64	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
65	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
66	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
67	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
68	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
69	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
70	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
71	Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
72	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
73	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
74	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
75	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
76	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
77	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
78	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
80	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
81	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
82	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
83	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
84	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
85	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
86	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
87	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
88	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
89	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
90	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
91	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.